Table 2.
Results of association study of G4925A on Lp(a) concentrations
| Group | βinverse norm | βoriginal | P-value | Variance explained (%)a |
|---|---|---|---|---|
| Unadjusted model | ||||
| KORA F4 all (n = 2892) | −0.122 | −8.1 | 0.006 | 0.2 |
| KORA F4 LMW only (n = 716) | −0.891 | −31.3 | 5.57e-38 | 20.6 |
| KORA F4 HMW only (n = 2176) | 0.054 | −2.5 | 0.231 | 0.02 |
| Adjusted model (isoform-adjusted) | ||||
| KORA F4 all (n = 2864) | −0.618 | −21.3 | 1.05e-55 | 6.1 |
| KORA F4 LMW only (n = 715) | −0.868 | −30.6 | 3.0e-36 | 19.3 |
| KORA F4 HMW only (n = 2149) | −0.310 | −10.0 | 1.69e-10 | 1.6 |
P-value, βinverse norm, and explained variance (R2) are based on linear regression from G4925A carrier status on inverse normal-transformed Lp(a) concentrations. Additional effect estimates were obtained from linear regression on the original Lp(a) scale in mg/dL (βoriginal).
a
For the adjusted model, this represents the variance explained by G4925A additionally to apo(a) isoforms.